- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Patent holdings for IPC class A61P 1/04
Total number of patents in this class: 3400
10-year publication summary
|
84
|
99
|
142
|
209
|
212
|
248
|
202
|
226
|
225
|
168
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2704 |
69 |
| Daiichi Sankyo Company, Limited | 1875 |
53 |
| AstraZeneca AB | 2872 |
50 |
| Osaka University | 3394 |
28 |
| Janssen Biotech, Inc. | 1564 |
24 |
| Ono Pharmaceutical Co., Ltd. | 430 |
23 |
| The Regents of the University of California | 20153 |
22 |
| Raqualia Pharma Inc. | 122 |
21 |
| Eisai R&D Management Co., Ltd. | 1218 |
20 |
| Dainippon Sumitomo Pharma Co., Ltd. | 181 |
19 |
| Meiji Co., Ltd. | 735 |
19 |
| Taisho Pharmaceutical Co., Ltd. | 863 |
19 |
| Astellas Pharma Inc. | 1071 |
18 |
| The University of Tokyo | 4229 |
18 |
| Ajinomoto Co., Inc. | 2306 |
17 |
| Cedars-Sinai Medical Center | 1167 |
17 |
| Daewoong Pharmaceutical Co., Ltd. | 323 |
16 |
| Nippon Shinyaku Co., Ltd. | 323 |
16 |
| Chugai Seiyaku Kabushiki Kaisha | 1371 |
14 |
| Mitsubishi Tanabe Pharma Corporation | 580 |
14 |
| Other owners | 2903 |